Organogenesis Holdings Inc. (NASDAQ: ORGO) stock jumped 0.78% on Tuesday to $2.58 against a previous-day closing price of $2.56. With 0.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.63 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.6150 whereas the lowest price it dropped to was $2.5000. The 52-week range on ORGO shows that it touched its highest point at $9.27 and its lowest point at $2.23 during that stretch. Beta for the stock currently stands at 1.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ORGO was down-trending over the past week, with a drop of -3.01%, but this was down by -1.15% over a month. Three-month performance dropped to -18.10% while six-month performance fell -52.83%. The stock lost -64.71% in the past year, while it has lost -4.09% so far this year. A look at the trailing 12-month EPS for ORGO yields 0.46 with Next year EPS estimates of 0.23. For the next quarter, that number is 0.06. This implies an EPS growth rate of 358.80% for this year and 88.00% for next year. EPS is expected to grow by 2.41% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 96.00%.
Float and Shares Shorts:
At present, 130.90 million ORGO shares are outstanding with a float of 64.70 million shares on hand for trading. On Oct 13, 2022, short shares totaled 5.68 million, which was 4.34% higher than short shares on Sep 14, 2022. In addition to Mr. Gary S. Gillheeney Sr. as the firm’s Pres, CEO & Director, Mr. David C. Francisco serves as its Chief Financial Officer.
Through their ownership of 46.30% of ORGO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 58.81% of ORGO, in contrast to 22.01% held by mutual funds. Shares owned by individuals account for 21.24%. As the largest shareholder in ORGO with 7.54% of the stake, BlackRock Fund Advisors holds 9,870,054 shares worth 9,870,054. A second-largest stockholder of ORGO, Soleus Capital Management LP, holds 6,626,063 shares, controlling over 5.06% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in ORGO, holding 4,302,969 shares or 3.29% stake. With a 4.05% stake in ORGO, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 5,298,928 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 1.44% of ORGO stock, is the second-largest Mutual Fund holder. It holds 1,884,061 shares valued at 5.07 million. Delaware Ivy Small Cap Growth Fun holds 1.28% of the stake in ORGO, owning 1,670,726 shares worth 4.49 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ORGO since 2 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ORGO analysts setting a high price target of $11.00 and a low target of $11.00, the average target price over the next 12 months is $11.00. Based on these targets, ORGO could surge 326.36% to reach the target high and rise by 326.36% to reach the target low. Reaching the average price target will result in a growth of 326.36% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ORGO will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of $0.13 being high and $0.12 being low. For ORGO, this leads to a yearly average estimate of $0.13. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Organogenesis Holdings Inc. surprised analysts by -$0.02 when it reported $0.04 EPS against a consensus estimate of $0.06. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is $0.06 and the low estimate is $0.05. The average estimate for the next quarter is thus $0.06.
Summary of Insider Activity:
Insiders traded ORGO stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 6,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 40 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 2,453,215 while 1,617,554 shares were sold.